The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 363.20
Bid: 363.00
Ask: 363.80
Change: 3.20 (0.89%)
Spread: 0.80 (0.22%)
Open: 357.00
High: 363.60
Low: 357.00
Prev. Close: 360.00
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

20 Feb 2024 07:00

RNS Number : 6754D
QinetiQ Group plc
20 February 2024
 

QinetiQ Group plc

20th February 2024

QinetiQ Group plc

Transaction in own shares

QinetiQ Group plc (the Company) announces that on 16th February 2024 it has purchased, in accordance with the authority granted by shareholders at the general meeting of the Company held on 6 February 2024, the following number of its ordinary shares of 1 pence each (Shares) on the London Stock Exchange pursuant to its existing £100 million share buyback programme which was announced on 16 January 2024.

The Company intends to cancel the purchased shares.

Description of Shares:

QinetiQ Group plc- ordinary shares of 1 pence each (ISIN: GB00B0WMWD03)

Date of transaction

19th February 2024

Number of Shares purchased:

119,827

Average price paid per Share (pence):

376.6669

Highest price paid per Share (pence):

378.0000

Lowest price paid per Share (pence):

374.6000

Broker:

Barclays Capital Securities Limited

 

Aggregate information:

Venue

Volume-weighted average price

Aggregated volume

Lowest price per share

Highest price per share

Aquis Exchange

3.7684

12,534

3.7580

3.7780

CBOE BXE

3.7682

8,803

3.7620

3.7780

CBOE CXE

3.7670

27,422

3.7500

3.7800

London Stock Exchange

3.7659

62,954

3.7460

3.7800

Turquoise

3.7670

8,114

3.7640

3.7680

 

This announcement is prepared on a trade basis. It is expected the shares purchased will be delivered to the Company within two working days. The total voting rights referred to below is prepared on a settlement basis.

Following the purchase of these shares, the remaining number of ordinary shares in issue will be 577,597,294. The Company does not hold any ordinary shares in treasury. Therefore, the total voting rights in the Company will be 577,597,294.

The figure of 577,597,294 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, a full breakdown of the individual trades made by Barclays Capital Securities Limited on behalf of the Company is available via the link below.

http://www.rns-pdf.londonstockexchange.com/rns/6754D_1-2024-2-19.pdf

This announcement will also be available on QinetiQ Group plc's website at https://www.qinetiq.com/en/investors.

Enquiries to:

John Haworth, Group Head of Investor Relations: +44 (0) 7920 545841

Lindsay Walls, Group Director Communications: +44 (0) 7793 427582

James Field, Company Secretary: +44 (0) 7841 662957

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSQKCBPOBKDFBD
Date   Source Headline
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023
10th May 20234:55 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSFourth Quarter Trading Update
12th Apr 202311:35 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSQinetiQ announces £259 million renewal of MSCA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.